Why Did Truist Lower IGM Biosciences' Price Target?

  • Truist has lowered the price target on IGM Biosciences Inc IGMS to $74 from $80.
  • The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA SNY collaboration deal. 
  • Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.
  • However, the analyst keeps a Buy rating on the shares and believes that IGM offers ample room for near-term catalysts to increase its value potential significantly.
  • Morgan Stanley maintains IGM Biosciences with an Equal-Weight and raises the price target from $25 to $30.
  • Earlier today, IGM Biosciences priced its underwritten public offering of 8.7 million shares at $23.00 per share, for gross proceeds of approximately $200.0 million. The offering will close by April 1.
  • Price Action: IGMS shares are down 7.87% at $27.17 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!